Ester Mejstrikova
Overview
Explore the profile of Ester Mejstrikova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hrusak O, Stancikova J, Vodickova E, Podolska T, Moricke A, Attarbaschi A, et al.
Pediatr Blood Cancer
. 2024 Oct;
72(1):e31394.
PMID: 39415351
Background: Auer rods (AuRs) are prominent intracellular structures found almost exclusively in myeloid cell malignancies, such as acute myeloid leukemia (AML), chronic and juvenile myelomonocytic leukemia and myelodysplastic syndrome. Extremely...
2.
Bakardjieva M, Pelak O, Wentink M, Glier H, Novak D, Stancikova J, et al.
Eur J Immunol
. 2024 Sep;
54(12):e2451004.
PMID: 39235410
Detailed knowledge of human B-cell development is crucial for the proper interpretation of inborn errors of immunity and malignant diseases. It is of interest to understand the kinetics of protein...
3.
Lizcova L, Prihodova E, Pavlistova L, Svobodova K, Mejstrikova E, Hrusak O, et al.
Mol Cytogenet
. 2024 May;
17(1):14.
PMID: 38783324
Background: T-cell acute lymphoblastic leukemia (T-ALL) represents a rare and clinically and genetically heterogeneous disease that constitutes 10-15% of newly diagnosed pediatric ALL cases. Despite improved outcomes of these children,...
4.
Zhang C, Chan K, Ng W, Cheung J, Sun Q, Wang H, et al.
Haematologica
. 2024 Apr;
109(9):2833-2845.
PMID: 38572553
Resistance to glucocorticoids (GC), the common agents for remission induction in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), poses a significant therapeutic hurdle. Therefore, dissecting the mechanisms shaping GC resistance...
5.
Buldini B, Varotto E, Maurer-Granofszky M, Gaipa G, Schumich A, Bruggemann M, et al.
Blood
. 2024 Jan;
143(17):1738-1751.
PMID: 38215390
In the effort to improve immunophenotyping and minimal residual disease (MRD) assessment in acute lymphoblastic leukemia (ALL), the international Berlin-Frankfurt-Münster (iBFM) Flow Network introduced the myelomonocytic marker CD371 for a...
6.
Verbeek M, Rodriguez B, Sedek L, Laqua A, Buracchi C, Buysse M, et al.
Cytometry B Clin Cytom
. 2023 Sep;
106(4):252-263.
PMID: 37740440
Presence of minimal residual disease (MRD), detected by flow cytometry, is an important prognostic biomarker in the management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, data-analysis remains mainly expert-dependent....
7.
Bugarin C, Antolini L, Buracchi C, Matarraz S, Coliva T, Van der Velden V, et al.
Haematologica
. 2023 Aug;
109(2):521-532.
PMID: 37534527
Diagnostic criteria for juvenile myelomonocytic leukemia (JMML) are currently well defined, however in some patients diagnosis still remains a challenge. Flow cytometry is a well established tool for diagnosis and...
8.
Mersakova S, Janikova K, Kalman M, Marcinek J, Grendar M, Vojtko M, et al.
Oncol Lett
. 2022 Jun;
24(1):231.
PMID: 35720495
The number of individuals diagnosed with colorectal cancer (CRC) has been on an alarming upward trajectory over the past decade. In some countries, this cancer represents one of the most...
9.
Vakrmanova B, Novakova M, riha P, Zaliova M, Fronkova E, Mejstrikova E, et al.
Pediatr Blood Cancer
. 2022 May;
69(9):e29779.
PMID: 35592935
Daratumumab, an anti-CD38 antibody, is used experimentally in the treatment of relapsed acute lymphoblastic leukemia (ALL). We treated five patients suffering from relapsed ALL with daratumumab. Four patients had T...
10.
Brouwer N, Matarraz S, Nierkens S, Hofmans M, Novakova M, da Costa E, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326734
Acute megakaryoblastic leukemia (AMKL) is a rare and heterogeneous subtype of acute myeloid leukemia (AML). We evaluated the immunophenotypic profile of 72 AMKL and 114 non-AMKL AML patients using the...